Associations - Libtayo (cemiplimab-rwlc)

PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1
No biomarker	Squamous Cell Skin Cancer	No biomarker	Squamous Cell Skin Cancer	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1
PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2
MSI-H/dMMR	Testicular Cancer	MSI-H/dMMR	Testicular Cancer	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2
PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2
PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2
No biomarker	Lung Non-Small Cell Squamous Cancer	No biomarker	Lung Non-Small Cell Squamous Cancer	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2
PD-L1 expression	Lung Non-Small Cell Squamous Cancer	PD-L1 expression	Lung Non-Small Cell Squamous Cancer	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B
EGFR wild-type	Lung Non-Small Cell Squamous Cancer	EGFR wild-type	Lung Non-Small Cell Squamous Cancer	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B
ROS1 wild-type	Lung Non-Small Cell Squamous Cancer	ROS1 wild-type	Lung Non-Small Cell Squamous Cancer	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B
ROS1 wild-type	Lung Non-Squamous Non-Small Cell Cancer	ROS1 wild-type	Lung Non-Squamous Non-Small Cell Cancer	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B
ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B
ALK wild-type	Lung Non-Small Cell Squamous Cancer	ALK wild-type	Lung Non-Small Cell Squamous Cancer	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	ipilimumab + cemiplimab-rwlc Sensitive: C3 – Early Trials ipilimumab + cemiplimab-rwlc Sensitive : C3	ipilimumab + cemiplimab-rwlc Sensitive: C3 – Early Trials ipilimumab + cemiplimab-rwlc Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive: C3 – Early Trials cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive : C3	cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive: C3 – Early Trials cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive : C3
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	ipilimumab + cemiplimab-rwlc Sensitive: C3 – Early Trials ipilimumab + cemiplimab-rwlc Sensitive : C3	ipilimumab + cemiplimab-rwlc Sensitive: C3 – Early Trials ipilimumab + cemiplimab-rwlc Sensitive : C3
HLA-A*24:02	Hepatocellular Cancer	HLA-A*24:02	Hepatocellular Cancer	cemiplimab-rwlc Sensitive: C3 – Early Trials cemiplimab-rwlc Sensitive : C3	cemiplimab-rwlc Sensitive: C3 – Early Trials cemiplimab-rwlc Sensitive : C3
HR negative	HER2 Negative Breast Cancer	HR negative	HER2 Negative Breast Cancer	cemiplimab-rwlc Sensitive: C3 – Early Trials cemiplimab-rwlc Sensitive : C3	cemiplimab-rwlc Sensitive: C3 – Early Trials cemiplimab-rwlc Sensitive : C3
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	cemiplimab-rwlc + REGN3767 Sensitive: C3 – Early Trials cemiplimab-rwlc + REGN3767 Sensitive : C3	cemiplimab-rwlc + REGN3767 Sensitive: C3 – Early Trials cemiplimab-rwlc + REGN3767 Sensitive : C3
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	ipilimumab + cemiplimab-rwlc Sensitive: C3 – Early Trials ipilimumab + cemiplimab-rwlc Sensitive : C3	ipilimumab + cemiplimab-rwlc Sensitive: C3 – Early Trials ipilimumab + cemiplimab-rwlc Sensitive : C3
LDH elevation	Melanoma	LDH elevation	Melanoma	cemiplimab-rwlc + REGN3767 Sensitive: C3 – Early Trials cemiplimab-rwlc + REGN3767 Sensitive : C3	cemiplimab-rwlc + REGN3767 Sensitive: C3 – Early Trials cemiplimab-rwlc + REGN3767 Sensitive : C3
PD-L1 expression	Lymphoma	PD-L1 expression	Lymphoma	cemiplimab-rwlc + isatuximab-irfc Sensitive: C3 – Early Trials cemiplimab-rwlc + isatuximab-irfc Sensitive : C3	cemiplimab-rwlc + isatuximab-irfc Sensitive: C3 – Early Trials cemiplimab-rwlc + isatuximab-irfc Sensitive : C3

Libtayo (cemiplimab-rwlc)

Associations
(29)

Associations
(29)

Libtayo (cemiplimab-rwlc)

Associations(29)

Associations(29)

Associations
(29)

Associations
(29)